Trial Profile

A Phase II Multi-center, Randomized, Single-blind, Placebo-controlled to Evaluate Safety and Efficacy of ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASC 42 (Primary) ; Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
Indications Hepatitis B
Focus Therapeutic Use
Sponsors Ascletis

03 Apr 2024 Status changed from active, no longer recruiting to completed.
26 Jun 2023 Results assessing the safety and efficacy of combined treatment andpharmacokinetic (PK) of ASC42 in CHB patients treated with ASC42combined with PEGylated interferon- alpha-2a and ETV presented in an Ascletis media release.
26 Jun 2023 According to an Ascletis media release, company announced Poster Presentation of this Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com